Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
Blood Advances|April 15, 2024
Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapiesAnna J Howard, Isabel Concepcion, Alice X Wang, et al.
Blood|May 10, 2024
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myelomaRoss S Firestone, Nicholas D Socci, Tala Shekarkhand, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
American Journal of Hematology|January 2, 2023
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approachMatthew J Pianko, Timothy Tiutan, Andriy Derkach, et al.
JCO Oncology Practice|September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances|April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapyIssam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Blood Cancer Journal|April 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myelomaHamza Hashmi, Tara Sebastian, Sridevi Rajeeve, et al.
Eclinicalmedicine|March 10, 2023
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort studyNeha Korde, Elizabet Tavitian, Donna Mastey, et al.
Blood Cancer Journal|May 31, 2024
Comparison of infectious complications with BCMA-directed therapies in multiple myelomaKarthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.
Pageof 9